Literature DB >> 12704387

Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.

Pamela M Pollock1, Karine Cohen-Solal, Raman Sood, Jin Namkoong, Jeffrey J Martino, Aruna Koganti, Hua Zhu, Christiane Robbins, Izabela Makalowska, Seung-Shick Shin, Yari Marin, Kathleen G Roberts, Laura M Yudt, Amy Chen, Jun Cheng, Arturo Incao, Heather W Pinkett, Christopher L Graham, Karen Dunn, Steven M Crespo-Carbone, Kerine R Mackason, Kevin B Ryan, Daniel Sinsimer, James Goydos, Kenneth R Reuhl, Michael Eckhaus, Paul S Meltzer, William J Pavan, Jeffrey M Trent, Suzie Chen.   

Abstract

To gain insight into melanoma pathogenesis, we characterized an insertional mouse mutant, TG3, that is predisposed to develop multiple melanomas. Physical mapping identified multiple tandem insertions of the transgene into intron 3 of Grm1 (encoding metabotropic glutamate receptor 1) with concomitant deletion of 70 kb of intronic sequence. To assess whether this insertional mutagenesis event results in alteration of transcriptional regulation, we analyzed Grm1 and two flanking genes for aberrant expression in melanomas from TG3 mice. We observed aberrant expression of only Grm1. Although we did not detect its expression in normal mouse melanocytes, Grm1 was ectopically expressed in the melanomas from TG3 mice. To confirm the involvement of Grm1 in melanocytic neoplasia, we created an additional transgenic line with Grm1 expression driven by the dopachrome tautomerase promoter. Similar to the original TG3, the Tg(Grm1)EPv line was susceptible to melanoma. In contrast to human melanoma, these transgenic mice had a generalized hyperproliferation of melanocytes with limited transformation to fully malignant metastasis. We detected expression of GRM1 in a number of human melanoma biopsies and cell lines but not in benign nevi and melanocytes. This study provides compelling evidence for the importance of metabotropic glutamate signaling in melanocytic neoplasia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704387     DOI: 10.1038/ng1148

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  125 in total

1.  mGlu Receptors and Cancerous Growth.

Authors:  Jessica Teh; Suzie Chen
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2011-10-25

Review 2.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells.

Authors:  Brian A Wall; Lumeng J Yu; Atif Khan; Bruce Haffty; James S Goydos; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2014-11-28       Impact factor: 4.693

Review 4.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 5.  Molecular pathways: dysregulated glutamatergic signaling pathways in cancer.

Authors:  Todd D Prickett; Yardena Samuels
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

6.  Regulation of mGluR1 expression in human melanocytes and melanoma cells.

Authors:  Hwa Jin Lee; Brian A Wall; Janet Wangari-Talbot; Suzie Chen
Journal:  Biochim Biophys Acta       Date:  2012-07-05

7.  The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.

Authors:  Maithao N Le; Joseph L-K Chan; Stephen A Rosenberg; Adam S Nabatian; Kim T Merrigan; Karine A Cohen-Solal; James S Goydos
Journal:  J Invest Dermatol       Date:  2010-05-27       Impact factor: 8.551

8.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma.

Authors:  Xiaomu Wei; Vijay Walia; Jimmy C Lin; Jamie K Teer; Todd D Prickett; Jared Gartner; Sean Davis; Katherine Stemke-Hale; Michael A Davies; Jeffrey E Gershenwald; William Robinson; Steven Robinson; Steven A Rosenberg; Yardena Samuels
Journal:  Nat Genet       Date:  2011-04-15       Impact factor: 38.330

9.  Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy.

Authors:  Mingjie Cui; Dominik J Naczynski; Margot Zevon; Craig K Griffith; Larisa Sheihet; Izmarie Poventud-Fuentes; Suzie Chen; Charles M Roth; Prabhas V Moghe
Journal:  Adv Healthc Mater       Date:  2013-03-12       Impact factor: 9.933

10.  Effects of G-protein mutations on skin color.

Authors:  Catherine D Van Raamsdonk; Karen R Fitch; Helmut Fuchs; Martin Hrabé de Angelis; Gregory S Barsh
Journal:  Nat Genet       Date:  2004-08-22       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.